

Resource Summary Report

Generated by ASWG on Aug 10, 2026

Brilliant Violet 711(TM) anti-human CD38

RRID:AB_2563811

Type: Antibody

Proper Citation

BioLegend Cat# 303528, RRID:AB_2563811

Antibody Information

URL: http://antibodyregistry.org/AB_2563811

Proper Citation: BioLegend Cat# 303528, RRID:AB_2563811

Target Antigen: CD38

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 711(TM) anti-human CD38

Description: This monoclonal targets CD38

Target Organism: human

Clone ID: Clone HIT2

Antibody ID: AB_2563811

Vendor: BioLegend

Catalog Number: 303528

Alternative Catalog Numbers: 303527

Record Creation Time: 20250819T212241+0000

Record Last Update: 20250819T224534+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 711(TM) anti-human CD38.

No alerts have been found for Brilliant Violet 711(TM) anti-human CD38.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Nunez D, et al. (2026) Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial. Molecular therapy. Advances, 34(1), 201663.

Gattinoni L, et al. (2026) Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse. Cell, 189(12), 3686.

Schmitt NC, et al. (2025) Early-Phase Trial of IAP Antagonist Tolinapant and Definitive Radiation in Cisplatin-Ineligible Patients with Advanced Head and Neck Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(14), 2910.

Poran A, et al. (2020) Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. Cell reports. Medicine, 1(8), 100141.

Chen Y, et al. (2020) Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. Cell, 183(6), 1496.

Syedbasha M, et al. (2020) Interferon-?? Enhances the Differentiation of Naive B Cells into Plasmablasts via the mTORC1 Pathway. Cell reports, 33(1), 108211.